Loading
Loading
Research Overview
Synthetic amylin analogue with three proline substitutions preventing aggregation; slows gastric emptying, suppresses postprandial glucagon, and activates AMY1-3 receptors in brainstem to promote satiety — complementing mealtime insulin action.
Amylin is co-secreted with insulin by pancreatic beta cells in response to meals. Its physiological roles include slowing gastric emptying, suppressing postprandial glucagon secretion, and promoting satiety. Type 1 diabetes patients are amylin-deficient (beta cell destruction) and many type 2 patients have impaired amylin secretion, contributing to postprandial glucose dysregulation.
Pramlintide is a synthetic analogue incorporating three proline substitutions that prevent the aggregation characteristic of native amylin, enabling formulation and subcutaneous injection. It is administered before meals as part of insulin therapy to address the amylin component of postprandial glucose control — reducing glucagon, slowing gastric emptying, and promoting post-meal satiety.
The critical safety consideration with pramlintide is the interaction with concurrent insulin: pramlintide reduces postprandial glucose, meaning mealtime insulin doses typically require reduction (30–50%) to prevent hypoglycaemia when pramlintide is initiated. This adjustment represents the primary complexity of pramlintide use in clinical practice.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, pramlintide (symlin) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pramlintide (Symlin) research is most relevant to protocols examining:
Mealtime amylin pathway research and postprandial glucose control
T1DM and T2DM adjunct therapy studies
Gastric emptying and glucagon suppression mechanism investigations
Researchers studying amylin-insulin combination for glucose management
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~50 minutes). Review data, confirm baseline recovery before any repeat protocol.
Synthetic amylin analogue with three proline substitutions preventing aggregation; slows gastric emptying, suppresses postprandial glucagon, and activates AMY1-3 receptors in brainstem to promote satiety — complementing mealtime insulin action.
| Parameter | Value |
|---|---|
| Dose range | 15–60 mcg pre-meal (T1DM) |
| Alt. dose 2 | 60–120 mcg pre-meal (T2DM) |
| Schedule | Before each meal |
| Route | Subcutaneous |
| Half-life | ~50 minutes |
especially on initiation)
Insulin (critical): severe hypoglycaemia risk when Pramlintide is used with mealtime insulin
insulin dose must be reduced by 50% on initiation; this is a black-box warning
Sulphonylureas (glipizide, glibenclamide, gliclazide)
additive hypoglycaemia risk
Alcohol: unpredictable blood glucose effects alongside Pramlintide
masks hypoglycaemia symptoms
Opioids: additive gastric emptying slowing
severe GI motility impairment and constipation risk
Anticholinergics (some antidepressants, bladder drugs): further slow gastric emptying
dangerous combined with Pramlintide
Cocaine / meth
blood glucose unpredictability and cardiovascular strain alongside a glucose-regulating compound
Cannabis (high THC)
appetite stimulation directly counteracts the satiety mechanism; blood glucose variability
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.